Anupam Rama

Shares of the thinly traded, micro-cap biotech Inflarx NV (NASDAQ: IFRX) were losing 90 percent of their value Wednesday following a failed clinical trial. ChemoCentryx Inc (NASDAQ: CCXI), which has a rival drug in its pipeline, traded down in sympathy  What Happened InflaRx...

The American Society of Clinical Oncology's 2018 annual meeting is scheduled to be held in Chicago, Illinois June 1-5. In a Thursday note, JPMorgan evaluated the prospects for Dynavax Technologies Corporation (NASDAQ: DVAX) in the coming month, especially ahead of the ASCO presentations....

JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech companies JPMorgan turned bearish on Monday.  The Rating Analyst Jessica Fye...

Opko Health Inc. (NASDAQ: OPKO) reported major fourth-quarter misses in both its top and bottom lines Thursday. The Street didn't react kindly. The Rating JPMorgan analysts Eric Joseph and Anupam Rama downgraded Opko to Underweight and removed its prior price target of $7. The Thesis The...

Analyzing the possibility of PTC Therapeutics, Inc. (NASDAQ: PTCT) receiving a complete response letter for its non-sense mutation Duchenne Muscular Dystrophy candidate Translarna, JPMorgan downgraded shares of the company. Taking out U.S. Translarna from its model, which would eliminate $200...

Following two key de-risking event, namely the second-quarter strategic update and hiring of an industry veteran as the chief financial officer, JP Morgan upgraded shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). The firm sees the new CFO hiring as a positive readthrough, signaling low...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) tumbled in Wednesday’s after-hours, after the company said it would miss the deadline for its latest 10-Q. As per an SEC filing, the 10-Q will be delayed because the Audit and Finance Committee of the company’s board of directors is...

JPMorgan has downgraded Merrimack Pharmaceuticals Inc (NASDAQ: MACK) to Neutral from Overweight and cut the price target to $7 from $8, citing the belief that shares would be range bound in the near to intermediate term amid the company's ongoing strategic review. Earlier this week, Merrimack...

JPMorgan’s Anupam Rama believes Ignyta Inc (NASDAQ: RXDX) is an emerging key player in the targeted drug development arena in oncology. Rama initiated coverage of the company with an Overweight rating and price target of $15. Underappreciated Asset “On the heels of promising phase 1/2...

Agios Pharmaceuticals Inc (NASDAQ: AGIO) presented “de-risking” data for its PKD program at the EHA. The stock has declined 25 percent since June 9. JPMorgan’s Anupam Rama upgraded the rating on the company from Neutral to Overweight, while raising the price target from $50 to $62...